Company Q&A | Dizhe Pharmaceuticals: Slight Quarterly Revenue Fluctuations Do Not Represent Overall Business Performance Trends

NightAirdropper · 2026-03-20T17:53:18+00:00

Dizhe Pharmaceuticals responded to investors' questions regarding the decline in sales in the fourth quarter, stating that fluctuations in a single quarter do not indicate a long-term trend. The company expects to achieve steady growth in 2025, with revenue reaching approximately 800 million yuan, an increase of about 120%. The company believes that the inclusion of its core products in the medical insurance catalog will promote sales growth.

NightAirdropper

2026-03-20 17:53:18

Abstract generation in progress

Gelonghui March 18 | An investor asked DiZhe Pharmaceuticals on the interactive platform: Based on the latest financial data, the company’s long-term growth trend shows that DiZhe Pharmaceuticals’ Q4 sales were 215 million yuan, compared to 235 million yuan in Q3, a quarter-over-quarter decrease of 20 million yuan, indicating a negative growth trend. What is the reason for the quarter-over-quarter decline in Q4 sales? Concerns about the company’s long-term growth trend. In the current market with fierce competition and constantly changing industry policies, how does the company assess the impact of this decline on its long-term growth strategy? What specific measures have been taken to ensure sustainable and stable growth in the future?

DiZhe Pharmaceuticals replied that slight fluctuations in quarterly revenue do not represent the overall business performance trend. The company will accelerate its commercialization process in 2025 to achieve steady growth. After entering the medical insurance system, the core products are showing a clear volume-up trend. It is expected that in 2025, the company’s revenue will reach about 800 million yuan, a year-on-year increase of approximately 120%. The sales situation in 2026 will be disclosed in the periodic reports.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes